NNBC-3 Europe study: a trial to improve risk estimation and risk adapted adjuvant chemotherapy in node negative breast cancer patients by using new uPA and PAI-1 and to analise the efficacy of a sequential FEC-taxane chemotherapy versus a standard FEC-chemotherapy regimen

F.Herbst; N.Harbeck; V.P.R.Mueller; A.Oben; C.Meisner; F.Sweep; M.Schmitt; F.Jaenicke; C.Thomssen

首页> 外文期刊>European Journal of Cancer Supplements >NNBC-3 Europe study: a trial to improve risk estimation and risk adapted adjuvant chemotherapy in node negative breast cancer patients by using new uPA and PAI-1 and to analise the efficacy of a sequential FEC-taxane chemotherapy versus a standard FEC-chemotherapy regimen

【24h】

NNBC-3 Europe study: a trial to improve risk estimation and risk adapted adjuvant chemotherapy in node negative breast cancer patients by using new uPA and PAI-1 and to analise the efficacy of a sequential FEC-taxane chemotherapy versus a standard FEC-chemotherapy regimen

机译：NNBC-3欧洲研究：一项试验，通过使用新的uPA和PAI-1改善结节阴性乳腺癌患者的风险估计和适应风险的辅助化疗，并分析顺序FEC-紫杉烷化疗与标准FEC化疗方案的疗效

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2004年第3期|共1页
作者
F.Herbst; N.Harbeck; V.P.R.Mueller; A.Oben; C.Meisner; F.Sweep; M.Schmitt; F.Jaenicke; C.Thomssen;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group. [J] . Kaufmann M, Graf E, Jonat W, Journal of Clinical Oncology . 2005,第31期

机译：绝经后，受体阴性的乳腺癌辅助，风险适应性化疗后他莫昔芬与对照组的比较：一项随机试验（GABG-IV D-93）-德国辅助乳腺癌小组。
2. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial [J] . M. Schmidt1* A. Victor2 D. Bratzel1 D. Boehm1 C. Cotarelo3 A. Lebrecht1 W. Siggelkow1 J. G. Hengstler4 A. Elsäßer2 M. Gehrmann5 H. -A. Lehr6 H. Koelbl1 G. von Minckwitz7 N. Harbeck8 and C. Thomssen9 Annals of Oncology . 2009,第2期

机译：通过淋巴结阴性乳腺癌的临床病理风险分类算法进行长期结果预测-佐剂，St Gallen与前瞻性随机淋巴结阴性乳腺癌-3（NNBC-3）试验中使用的新型风险算法之间的比较
3. Long-term prognostic impact of risk classifications in node-negative breast cancer – comparison between Adjuvant!, St. Gallen, and a novel risk algorithm used in the prospectively randomized Node-Negative-Breast-Cancer-3 trial (NNBC-3) [J] . M.Schmidt, A.Victor, D.Bohm, European Journal of Cancer Supplements . 2008,第7期

机译：风险分类在淋巴结阴性乳腺癌中的长期预后影响–比较Adjuvant！，St。Gallen和在前瞻性随机Node-Negative-Breast-Cancer-3试验（NNBC-3）中使用的新型风险算法
4. Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer [O] . Nadia Harbeck, Manfred Schmitt, Martina Vetter, 2008

机译：前瞻性生物标志物试验Chemo N0和NNBC-3 Europe验证了淋巴结阴性乳腺癌中入侵标志物uPA和PAI-1的临床应用
5. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. [O] . Schmidt, M., Victor, A., Bratzel, D., 2009

机译：通过淋巴结阴性乳腺癌的临床病理风险分类算法进行长期结果预测-比较佐剂，St Gallen和前瞻性随机淋巴结阴性乳腺癌3（NNBC-3）试验中使用的新型风险算法。

NNBC-3 Europe study: a trial to improve risk estimation and risk adapted adjuvant chemotherapy in node negative breast cancer patients by using new uPA and PAI-1 and to analise the efficacy of a sequential FEC-taxane chemotherapy versus a standard FEC-chemotherapy regimen

著录项

相似文献

相关主题

期刊订阅